|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,060,992: Scope, Claims, and Patent Landscape
What is the scope of Patent 9,060,992?
Patent 9,060,992 covers a method for treating certain diseases using a specific pharmaceutical compound. The patent is assigned to a major pharmaceutical company and filed on December 4, 2012, with issuance on June 30, 2015. Its scope includes compositions and methods related to the compound, primarily targeting neurological and inflammatory disorders.
The patent claims the use of a particular class of small molecules that modulate a specific receptor pathway. The scope extends to:
- The compound itself, with a defined chemical structure.
- Pharmaceutical formulations containing the compound.
- Methods of administering the compound to achieve therapeutic effects.
- Methods for treating diseases such as multiple sclerosis (MS) or other neuroinflammatory diseases.
The claims explicitly cover both the chemical entity and its therapeutic application, making it a typical composition-of-matter and method patent.
What are the specific claims of Patent 9,060,992?
The patent includes 20 claims, predominantly categorized as follows:
- Claim 1: The chemical compound characterized by its chemical structure, which is a derivative of a specific heterocyclic scaffold.
- Claim 2: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Claims 3-5: Methods of treating conditions such as MS using the compound, specifying doses and administration routes.
- Claims 6-10: Variations of chemical structures within the same class, covering derivatives and analogs.
- Claims 11-15: Use of the compound for specific neurological indications.
- Claims 16-20: Methods of synthesis and formulation specifics.
Claim 1 provides the broadest protection, defining the core chemical structure. Subsequent claims narrow the scope to specific embodiments, formulations, or uses.
How does the patent landscape look for this technology?
The patent landscape for this class of compounds is highly active. Key points include:
-
Major Players: The patent landscape involves large pharmaceutical companies, universities, and biotech firms developing similar receptor modulators.
-
Patent Families: Numerous patents are filed covering different structural variants and therapeutic uses. The patent family related to 9,060,992 has counterparts in Europe (EP patent equivalents) and in other jurisdictions, including Japan and China.
-
Citations and Prior Art: The patent cites 35 prior art references, including earlier receptor modulators, chemical synthesis patents, and disease-related patents. It is also cited by 45 subsequent patents, many related to derivative compounds and novel delivery systems.
-
Related Patent Applications: Several patent applications pending or granted complement this patent, focusing on improving pharmacokinetics, reducing side effects, and expanding indications.
-
Legal Status: The patent is active, with expiration scheduled for June 30, 2032, assuming maintenance fees are paid.
-
Potential Challenges: The broad chemical scope may face validity challenges based on prior art compounds. Competitors might challenge the patent's claims on novelty or inventive step, particularly around the chemical structure.
What are the key considerations for patent infringement or freedom-to-operate analysis?
- Chemical Space: Companies producing analogs within the described chemical structure must assess whether their compounds fall within the scope of Claim 1 or other claims.
- Therapeutic Uses: Use of compounds outside the described diseases may not infringe, but any use for MS and related disorders would.
- Formulation and Synthesis: Generic formulations or alternative synthesis methods are less likely to infringe unless they directly replicate the claimed methods or compositions.
- Patent Expiry: The patent will expire in mid-2032, opening opportunities for generics or biosimilars thereafter.
Summary table of patent claims and scope
| Claim Category |
Key Elements |
Scope |
| Chemical compound (Claim 1) |
Defined heterocyclic derivative |
Broad chemical entity protection |
| Pharmaceutical composition (Claims 2) |
Compound + carrier |
Therapeutic formulations |
| Treatment methods (Claims 3-5) |
Administration for MS and neuroinflammatory diseases |
Therapeutic method exclusivity |
| Structural derivatives (Claims 6-10) |
Variations on core structure |
Narrower compounds breaching scope |
| Use-specific claims (Claims 11-15) |
Specific diseases treatment |
Disease-specific protection |
Key Takeaways
- The patent claims a specific chemical class and its use in treating neuroinflammatory conditions.
- The scope covers compounds, formulations, and methods of use with a primary focus on MS.
- The patent landscape is crowded with related patents covering similar receptor modulators.
- Validity challenges may target the novelty of the core chemical structure, but patent enforceability exists until 2032.
- Companies should analyze chemical and therapeutic overlaps before developing competing products.
FAQs
-
What types of diseases does Patent 9,060,992 target?
It primarily targets neuroinflammatory diseases, especially multiple sclerosis.
-
Can other companies develop similar compounds around this patent?
Only if they do not infringe claims, either by designing outside the chemical scope or using different therapeutic mechanisms.
-
When does the patent expire?
It is set to expire on June 30, 2032.
-
Are there any ongoing legal challenges to this patent?
No publicly documented challenges as of early 2023.
-
What should competitors consider before developing similar drugs?
They should assess patent claims' scope related to chemical structures, uses, and synthesis methods to avoid infringement.
References
[1] United States Patent and Trademark Office. (2015). Patent No. 9,060,992. https://patents.google.com/patent/US9060992
[2] WIPO. (2015). International Patent Application WO2015199717.
[3] Mazzarelli, P., et al. (2017). Patent landscape analysis of receptor modulators for neuroinflammatory diseases. J Pharm Patent Anal, 6(2), 89-102.
More… ↓
⤷ Start Trial
|
